



# PRESS RELEASE

## THE OFFER OF QIAGEN ON IPSOGEN WAS A SUCCESS

**Marseille, France, January 4, 2012** – As announced by the AMF on November 29, 2011, QIAGEN holds, pursuant to its public offer on IPSOGEN, 89.30% of share capital and 86.47% of voting rights in IPSOGEN. This outcome is a tribute to the successful offer by QIAGEN, which provided IPSOGEN shareholders with an opportunity for a substantial premium and immediate liquidity on their investment in IPSOGEN.

QIAGEN and IPSOGEN are truly delighted and will re-focus from the transaction activities to the integration of IPSOGEN within the QIAGEN group.

Peer Schatz, CEO of QIAGEN, stated *"We are extremely pleased with the outcome of the offer on IPSOGEN which goes to show not only that the offering price was set right but also how meaningful the planned integration of IPSOGEN within the QIAGEN group was. Both QIAGEN and IPSOGEN teams shall now be fully devoted to the integration of IPSOGEN and to the implementation of the ambitious roadmap jointly developed with IPSOGEN, especially the setting-up of a center of excellence in Marseille for the development of nucleic acids-based assays"*.

Vincent Fert, CEO of IPSOGEN, stated: *"Since its creation, IPSOGEN has demonstrated the value of delivering innovative molecular tests to the oncology community for the benefit of patients and has proven to be an outstanding investment for its shareholders, as was demonstrated by the interest expressed by QIAGEN and the undeniable success of the offer made by it. We are genuinely proud to have contributed to this collective adventure, and to pursue it within the QIAGEN group, which shall offer the company and its employees an incredible environment for the development of our activities in Marseille. I wish to extend a heartfelt thanks to the shareholders who placed their trust in us from the start"*.

QIAGEN reserves the right to continue purchasing IPSOGEN shares, depending on market conditions.



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

## About IPSOGEN

IPSOGEN, "Cancer Profiler," develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, IPSOGEN is also targeting breast cancer. Its goal will be to provide diagnostic information that remained unavailable until now.

IPSOGEN is, since July 2011, a subsidiary of the QIAGEN group. As of June 30, 2011, IPSOGEN employed 75 people. Its headquarters are located in Marseille, France.

To find out more, visit [www.ipsogen.com](http://www.ipsogen.com).

## About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control.

QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.

QIAGEN employs nearly 3,600 people in over 30 locations worldwide.

Further information about QIAGEN can be found at [www.qiagen.com](http://www.qiagen.com).

## Contacts

---

### IPSOGEN

#### **Pascale Boissel**

CFO

Tel: + 33 (0)4 9129 3090

[pascale.boissel@ipsogen.com](mailto:pascale.boissel@ipsogen.com)

#### **Vincent Fert**

CEO

Tel: + 33 (0)4 9129 3090

[fert@ipsogen.com](mailto:fert@ipsogen.com)

#### **NewCap.**

Financial communication  
& Investor relations

#### **Axelle Vuillermet & Pierre Laurent**

Tel: + 33 (0)1 44 71 94 93

[ipsogen@newcap.fr](mailto:ipsogen@newcap.fr)

**ALIPS**  
**LISTED**  
**NYSE**  
**ALTERNEXT**